Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.

被引：0
|
作者：
Long, Georgina V.
Luke, Jason J.
Khattak, Muhammad
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Wu, Larry
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M.
Ascierto, Paolo Antonio
机构：
[1] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[4] Edith Cowan Univ, Fiona Stanley Hosp, Perth, WA, Australia
[5] Hosp Univ Virgen Macarena, Seville, Spain
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[8] IRCCS San Martino Polyclin Hosp, Genoa, Italy
[9] Poznan Univ Med Sci, Greater Poland Canc Ctr, Poznan, Poland
[10] IOV IRCCS, Ist Oncol Veneto, Padua, Italy
[11] Gustave Roussy, Villejuif, France
[12] Univ Paris Saclay, Villejuif, France
[13] Aix Marseille Univ, AP HM Hosp, Marseille, France
[14] Dermopath Inst Immaculate IDI IRCCS, Rome, Italy
[15] Univ Hosp Essen, Essen, Germany
[16] German Canc Consortium Partner Site, Essen, Germany
[17] Univ Sydney, Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia
[18] Univ Sydney, Melanoma Inst Australia, Blacktown Hosp, Sydney, NSW, Australia
[19] Merck & Co Inc, Kenilworth, NJ USA
[20] Univ Med Ctr Utrecht, Princess Maxima Ctr, Utrecht, Netherlands
[21] Inst Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BA9500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
    Long, G. V.
    Luke, J.
    Khattak, M. A.
    de la Cruz Merino, L.
    Del Vecchio, M.
    Rutkowski, P.
    Spagnolo, F.
    Mackiewicz, J.
    Chiarion-Sileni, V.
    Kirkwood, J. M.
    Robert, C.
    Grob, J. J.
    de Galitiis, F.
    Schadendorf, D.
    Carlino, M. S.
    Wu, L.
    Fukunaga-Kalabis, M.
    Krepler, C.
    Eggermont, A. M. M.
    Ascierto, P. A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 95 - 95
  • [2] Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Khattak, Muhammad Adnan
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M. M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Larry
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [3] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14)
  • [4] Phase III KEYNOTE-716 Study of Pembrolizumab (KEYTRUDA®) as adjuvant Therapy for Patients with resected Stage IIB or IIC Melanoma: significant Improvement in distant metastasis-free Survival versus Placebo
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [5] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
    Long, Georgina, V
    Luke, Jason J.
    Khattak, Muhammad A.
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Mohr, Peter
    Dummer, Reinhard
    Gershenwald, Jeffrey E.
    Yoon, Charles H.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Ascierto, Paolo A.
    [J]. LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
  • [6] Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma
    Long, Georgina, V
    Luke, Jason J.
    Fukunaga-Kalabis, Mizuho
    Asierto, Paolo A.
    [J]. LANCET ONCOLOGY, 2023, 24 (01): : E8 - E8
  • [7] Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.
    Carlino, Matteo S.
    Ascierto, Paolo Antonio
    Eggermont, Alexander M.
    Gershenwald, Jeffrey E.
    Grob, Jean Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick I.
    Scolyer, Richard A.
    Sondak, Vernon K.
    Yoon, Charles
    Poklepovic, Andrew Stewart
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Luke, Jason J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
    Luke, Jason J.
    Rutkowski, Piotr
    Queirolo, Paola
    Del Vecchio, Michele
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    de la Cruz-Merino, Luis
    Khattak, Muhammad A.
    Schadendorf, Dirk
    Long, Georgina, V
    Ascierto, Paolo A.
    Mandala, Mario
    De Galitiis, Federica
    Haydon, Andrew
    Dummer, Reinhard
    Grob, Jean-Jacques
    Robert, Caroline
    Carlino, Matteo S.
    Mohr, Peter
    Poklepovic, Andrew
    Sondak, Vernon K.
    Scolyer, Richard A.
    Kirkwood, John M.
    Chen, Ke
    Diede, Scott J.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    [J]. LANCET, 2022, 399 (10336): : 1718 - 1729
  • [9] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
    Schadendorf, Dirk
    Luke, Jason John
    Ascierto, Paolo A.
    Long, Georgina, V
    Rutkowski, Piotr
    Khattak, Adnan
    Del Vecchio, Michele
    de la Cruz-Merino, Luis
    Mackiewicz, Jacek
    Sileni, Vanna Chiarion
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    Dummer, Reinhard
    Carlino, Matteo S.
    Zhao, Yujie
    Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander
    Scolyer, Richard A.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [10] KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
    Luke, Jason J.
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Gershenwald, Jeffrey E.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina, V
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick
    Scolyer, Richard A.
    Yoon, Charles H.
    Poklepovic, Andrew
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    [J]. FUTURE ONCOLOGY, 2020, 16 (03) : 4429 - 4438
12345